As of the last check, shares of biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens,
Oncternal Therapeutics Inc. (ONCT) stock soared 2.42% to $2.96 in the pre-market trading as the company raised the size of the formerly publicized offering and
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.